Efficacy of Oral Ginger (Zingiber officinale) for Dysmenorrhea: A Systematic Review and Meta-Analysis - PubMed (original) (raw)

Review

Efficacy of Oral Ginger (Zingiber officinale) for Dysmenorrhea: A Systematic Review and Meta-Analysis

Chen X Chen et al. Evid Based Complement Alternat Med. 2016.

Abstract

This systematic review examines the efficacy of oral ginger for dysmenorrhea. Key biomedical databases and grey literature were searched. We included randomized controlled trials comparing oral ginger against placebo or active treatment in women with dysmenorrhea. Six trials were identified. Two authors independently reviewed the articles, extracted data, and assessed risk of bias. Discrepancies were resolved by consensus with a third reviewer. We completed a narrative synthesis of all six studies and exploratory meta-analyses of three studies comparing ginger with placebo and two studies comparing ginger with a nonsteroidal anti-inflammatory drug (NSAID). Ginger appeared more effective for reducing pain severity than placebo. The weighted mean difference on a 10 cm visual analogue scale was 1.55 cm (favoring ginger) (95% CI 0.68 to 2.43). No significant difference was found between ginger and mefenamic acid (an NSAID). The standardized mean difference was 0 (95% CI -0.40 to 0.41). Available data suggest that oral ginger could be an effective treatment for menstrual pain in dysmenorrhea. Findings, however, need to be interpreted with caution because of the small number of studies, poor methodological quality of the studies, and high heterogeneity across trials. The review highlights the need for future trials with high methodological quality.

PubMed Disclaimer

Figures

Figure 1

Figure 1

PRISMA flow diagram.

Figure 2

Figure 2

Risk of bias summary: review authors' judgments about each risk of bias domain for each included study.

Figure 3

Figure 3

Forest plot for ginger versus placebo, pain severity (10 cm VAS).

Figure 4

Figure 4

Forest plot of ginger versus NSAID (specifically mefenamic acid), pain severity.

Similar articles

Cited by

References

    1. International Association for the Study of Pain Task Force on Taxonomy. Classification of Chronic Pain. 2nd. 2011, http://www.iasp-pain.org/
    1. Dawood M. Y. Primary dysmenorrhea: advances in pathogenesis and management. Obstetrics & Gynecology. 2006;108(2):428–441. doi: 10.1097/01.aog.0000230214.26638.0c. - DOI - PubMed
    1. Ju H., Jones M., Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiologic Reviews. 2014;36(1):104–113. doi: 10.1093/epirev/mxt009. - DOI - PubMed
    1. Dawood M. Y. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. The American Journal of Medicine. 1988;84(5):23–29. doi: 10.1016/0002-9343(88)90473-1. - DOI - PubMed
    1. Vincent K., Warnaby C., Stagg C. J., Moore J., Kennedy S., Tracey I. Dysmenorrhoea is associated with central changes in otherwise healthy women. Pain. 2011;152(9):1966–1975. doi: 10.1016/j.pain.2011.03.029. - DOI - PubMed

Publication types

LinkOut - more resources